NCT05157165

Convalescent Plasma in Hospitalized COVID-19 Patients

Convalescent Plasma in Hospitalized COVID-19 Patients: a Single Center Experience

• Status: No Longer Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: Azienda Socio Sanitaria Territoriale di Mantova · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

The study assesses the efficacy and safety of administration of hyperimmune plasma in hospitalized COVID-19 patients. Efficacy was measured as 28-day mortality following convalescent plasma transfusion. Safety was measured as the rate of adverse reactions. to plasma infusion.

Detailed description

Inclusion criteria: Adult inpatients with a severe form of COVID-19 have been enrolled, with at least one of the following inclusion criteria: 1) tachypnea with respiratory rate (RR) \> 30 breaths/min; 2) oxygen saturation (SpO2) ≤ 93% at rest and in room air; 3) partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ≤ 200 mmHg, 4) radiological picture and/or chest CT scan showing signs of interstitial disease and/or rapid progression of lung involvement. Primary outcome: Overall mortality at 28 days after hospitalization Secondary outcome: Adverse reaction to plasma transfusion.

Conditions

• COVID-19

Interventions

Type	Name	Description
BIOLOGICAL	Convalescent plasma	Hyperimmune plasma from convalescent COVID-19 donors with titre 1:80 or more

Timeline

• First posted: 2021-12-14
• Last updated: 2023-07-21